Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Journal
European journal of cancer (Oxford, England : 1990)
Journal Volume
167
Pages
1
Date Issued
2022-05
Author(s)
Kudo, Masatoshi
Finn, Richard S
Edeline, Julien
Cattan, Stéphane
Ogasawara, Sadahisa
Palmer, Daniel H
Verslype, Chris
Zagonel, Vittorina
Fartoux, Laetitia
Vogel, Arndt
Sarker, Debashis
Verset, Gontran
Chan, Stephen L
Knox, Jennifer
Daniele, Bruno
Yau, Thomas
Gurary, Ellen B
Siegel, Abby B
Wang, Anran
Zhu, Andrew X
Abstract
Pembrolizumab, a PD-1 inhibitor, demonstrated anti-tumour activity and tolerability in patients treated with sorafenib and with advanced hepatocellular carcinoma in KEYNOTE-224. Longer-term efficacy and safety after ∼2.5 years of additional follow-up are reported.
Subjects
Advanced hepatocellular carcinoma; Anti-PD-1; Long-term treatment; Pembrolizumab
SDGs
Publisher
ELSEVIER SCI LTD
Type
journal article